Market Overview:
The global poliovirus vaccine market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of polio, increasing government initiatives for vaccination, and growing demand for oral polio vaccine (OPV). However, the high cost of vaccines and lack of awareness about vaccinations are some factors that could hamper the growth of this market. The global poliovirus vaccine market is segmented on the basis of type, application, and region. On the basis of type, it is divided into inactivated polio vaccine (IPV) and oral polio vaccine (OPV). OPV is further classified into monovalent OPV and bivalent OPV. On the basis of application, it is segmented into public sector and private sector. Regionally, it is analyzed across North America, Latin America Europe Asia Pacific Middle East & Africa (MEA).
Product Definition:
A vaccine used to prevent poliomyelitis, an acute viral disease that may cause paralysis. The vaccine is made from a killed virus and is given by injection.
Inactivated Polio Vaccine (IPV):
Inactivated Polio Vaccine (IPV) is a vaccine that prevents poliomyelitis. It's created by heating the virus in the laboratory to kill all of its harmful components, so it can't cause disease. The vaccine was first used in 1955 and has been continually updated since then to make sure it contains all of the active ingredients needed to prevent disease.
The World Health Organization (WHO).
Oral Polio Vaccine (OPV):
Oral polio vaccine (OPV) is a live, attenuated virus vaccine used to prevent disease caused by the Poliovirus. It was first introduced in England and Wales in 1988 and since then it has been widely used across the world especially in developing countries like India, Brazil, etc. OPV is an inexpensive vaccine as compared to its counterparts; however, there are no licensed commercial vaccines for poliomyletis that are available commercially today.
Application Insights:
Public health application of poliovirus vaccines accounted for the largest share of more than 60.0% in 2017. This is attributed to the global eradication of wild polio viruses and complete cessation of transmission from 1988 to 2005 due to implementation of the Global Polio Eradication Initiative (GPEI). The GPEI was a joint effort by WHO, national governments, international organizations and donor countries to stop the spread of wild poliovirus globally.
The use in immunization against vaccine-derived poliomyelitis has declined since its introduction as an alternative method for controllingpolio incidence through vaccination campaigns using OPV or IPV doses multiple times at intervals that are sufficient for immunity against infection with type 1 virus or residuals thereof (maintenance immunization). As a result, usage rates have declined significantly over past few years across all age groups below 5 years which may hinder market growth over forecast period.
Regional Analysis:
The global poliovirus vaccine market is dominated by the North American region, which accounted for a share of over 60.0% in 2017. This can be attributed to the fact that most of the countries in this region have been polio-free since last three years and are thus considered as high-risk areas for transmission of this virus. Moreover, government initiatives coupled with high healthcare expenditure levels in this region are some other factors contributing toward a large market share of North America.
However, Asia Pacific is anticipated to grow at an exponential rate throughout the forecast period owing to increasing number of reported cases across various countries such as India and Pakistan and low vaccination coverage especially among children below 5 years old. In addition, lack of awareness about these vaccines among parents will also boost growth during the forecast period along with continuous government efforts towards its distribution through mass media advertising campaigns etc., which has resulted into higher revenue generation from Asian markets compared to other regions over past few years (Table 1).
Growth Factors:
- Increasing incidence of poliomyelitis across the globe
- Growing awareness about the benefits of vaccination against polio
- Rising demand for safe and effective vaccines
- Technological advancements in vaccine development and production processes
- increasing government funding for polio vaccine research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Poliovirus Vaccine Market Research Report
By Type
Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)
By Application
Public, Private
By Companies
Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological, IMBCA, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Poliovirus Vaccine Market Report Segments:
The global Poliovirus Vaccine market is segmented on the basis of:
Types
Inactivated Polio Vaccine (IPV), Oral Polio Vaccine (OPV)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Public, Private
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- GSK
- Bibcol
- Serum Institute
- Tiantan Biological
- IMBCA
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
Highlights of The Poliovirus Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inactivated Polio Vaccine (IPV)
- Oral Polio Vaccine (OPV)
- By Application:
- Public
- Private
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Poliovirus Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Poliovirus vaccine is a vaccine that helps protect against poliovirus. It is made from dead or weakened viruses and is given by injection. Poliovirus vaccine can help prevent polio, a serious childhood illness.
Some of the key players operating in the poliovirus vaccine market are Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological, IMBCA, Panacea Biotec Ltd, Bio-Med, Halfkin Bio-Pharmaceuticals.
The poliovirus vaccine market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Poliovirus Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Poliovirus Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Poliovirus Vaccine Market - Supply Chain
4.5. Global Poliovirus Vaccine Market Forecast
4.5.1. Poliovirus Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Poliovirus Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Poliovirus Vaccine Market Absolute $ Opportunity
5. Global Poliovirus Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Poliovirus Vaccine Market Size and Volume Forecast by Type
5.3.1. Inactivated Polio Vaccine (IPV)
5.3.2. Oral Polio Vaccine (OPV)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Poliovirus Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Poliovirus Vaccine Market Size and Volume Forecast by Application
6.3.1. Public
6.3.2. Private
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Poliovirus Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Poliovirus Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Poliovirus Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Poliovirus Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Poliovirus Vaccine Demand Share Forecast, 2019-2026
9. North America Poliovirus Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Poliovirus Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Poliovirus Vaccine Market Size and Volume Forecast by Application
9.4.1. Public
9.4.2. Private
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Poliovirus Vaccine Market Size and Volume Forecast by Type
9.7.1. Inactivated Polio Vaccine (IPV)
9.7.2. Oral Polio Vaccine (OPV)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Poliovirus Vaccine Demand Share Forecast, 2019-2026
10. Latin America Poliovirus Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Application
10.4.1. Public
10.4.2. Private
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Poliovirus Vaccine Market Size and Volume Forecast by Type
10.7.1. Inactivated Polio Vaccine (IPV)
10.7.2. Oral Polio Vaccine (OPV)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Poliovirus Vaccine Demand Share Forecast, 2019-2026
11. Europe Poliovirus Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Poliovirus Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Poliovirus Vaccine Market Size and Volume Forecast by Application
11.4.1. Public
11.4.2. Private
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Poliovirus Vaccine Market Size and Volume Forecast by Type
11.7.1. Inactivated Polio Vaccine (IPV)
11.7.2. Oral Polio Vaccine (OPV)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Gowth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Poliovirus Vaccine Demand Share, 2019-2026
12. Asia Pacific Poliovirus Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Application
12.4.1. Public
12.4.2. Private
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Poliovirus Vaccine Market Size and Volume Forecast by Type
12.7.1. Inactivated Polio Vaccine (IPV)
12.7.2. Oral Polio Vaccine (OPV)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Poliovirus Vaccine Demand Share, 2019-2026
13. Middle East & Africa Poliovirus Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Application
13.4.1. Public
13.4.2. Private
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Poliovirus Vaccine Market Size and Volume Forecast by Type
13.7.1. Inactivated Polio Vaccine (IPV)
13.7.2. Oral Polio Vaccine (OPV)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Poliovirus Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Poliovirus Vaccine Market: Market Share Analysis
14.2. Poliovirus Vaccine Distributors and Customers
14.3. Poliovirus Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bibcol
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Serum Institute
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tiantan Biological
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. IMBCA
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Panacea Biotec Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bio-Med
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Halfkin Bio-Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook